// App-Quantinova.ai

: Impact of stable state symptoms on the future burden of COPD exacerbations

Researchers

Presenter

  • Alexander Mackay

Principal Investigators

  • Konstantinos Kostikas

  • Stefan-Marian Frent

  • Pascal Pfister

  • Pankaj Goyal

  • Pritam Gupta

  • Donald Banerji

  • Francesco Patalano

  • Jadwiga A. Wedzicha

Medical Centers

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • Novartis AG, Basel, Switzerland

  • Medical Semiotics, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • Airway Disease Infection Section, National Heart and Lung Institute (NHLI), Imperial College London, London, United Kingdom.

Locations

  • United Kingdom

  • Switzerland

  • Romania

  • India

  • United States

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • salmeterol + fluticasone

  • Seebri Breezhaler

  • Fluticasone

  • Fluticasone furoate

  • indacaterol

  • Salmeterol Xinafoate

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved